ASCO 2025

Perspective Therapeutics brings energy to the radiopharma world
BioSpace
Fri, 06/6/25 - 12:02 pm
Perspective Therapeutics
radiopharma
neuroendocrine tumors
ASCO 2025
With ADCs on the rise, drugmakers embrace a new oncology pillar
Pharma Voice
Fri, 06/6/25 - 11:36 am
oncology
ASCO 2025
antibody-drug conjugates
Daiichi Sankyo
AstraZeneca
Enhertu
Bispecific cancer drugs, data caveats and funding alarms: 3 takeaways from ASCO
BioPharma Dive
Thu, 06/5/25 - 11:30 am
ASCO 2025
cancer
oncology
bispecific antibodies
funding
breast cancer
Daiichi Sankyo struck gold with ‘ADC’ cancer drugs. Its new CEO has to figure out what’s next.
BioPharma Dive
Thu, 06/5/25 - 09:46 am
ASCO 2025
Daiichi Sankyo
antibody-drug conjugates
Hiroyuki Okuzawa
Enhertu
Datroway
ASCO25: Imunon shares positive results from trial of IMNN-001 for ovarian cancer
Clinical Trials Arena
Wed, 06/4/25 - 09:45 am
ASCO 2025
Imunon
IMNN-001
ovarian cancer
clinical trials
ASCO25: AbbVie flexes ADC Phase I data as NSCLC market opportunity beckons
Clinical Trials Arena
Tue, 06/3/25 - 11:03 pm
AbbVie
ASCO 2025
non-small cell lung cancer
telisotuzumab adizutecan
ASCO 2025: GSK’s Jemperli fails to show OS benefit in 1L advanced ovarian cancer
Clinical Trials Arena
Tue, 06/3/25 - 10:58 pm
ASCO 2025
GSK
Jemperli
clinical tirals
ovarian cancer
ASCO25: Genmab’s Rina-S en route to ‘blockbuster potential’ amid further positive data
Clinical Trials Arena
Tue, 06/3/25 - 10:54 pm
ASCO 2025
Genmab
Rina-S
endometrial cancer
Bayer drug could ease side effects of common breast cancer treatment, detailed data show
BioPharma Dive
Tue, 06/3/25 - 10:51 pm
Bayer
elinzanetant
hot flashes
ASCO 2025
breast cancer
ASCO: OSE shares 65% overall survival rate behind therapeutic cancer vaccine's phase 2 win
Fierce Biotech
Tue, 06/3/25 - 11:14 am
ASCO 2025
OSE Immunotherapeutics
vaccines
pancreatic cancer
clinical trials
Tedopi
ASCO: Kura, Kyowa reveal 23% remission rate behind oral leukemia drug's phase 2 win
Fierce Biotech
Tue, 06/3/25 - 10:57 am
Kura Oncology
Kyowa Kirin
ASCO 2025
leukemia
ziftomenib
ASCO: Bristol Myers CMO brushes off LAG-3 concern in lung cancer after Opdualag's adjuvant melanoma flop
Fierce Pharma
Tue, 06/3/25 - 10:52 am
ASCO 2025
Bristol Myers Squibb
Opdualag
skin cancer
melanoma
ASCO25: Trodelvy and Keytruda to become new standard of care for frontline TNBC
Clinical Trials Arena
Mon, 06/2/25 - 11:24 pm
ASCO 2025
Gilead Sciences
Merck
Trodelvy
Keytruda
triple negative breast cancer
Gilead's CAR-T cell therapy shows promise in deadly brain cancer
MSN/Reuters
Mon, 06/2/25 - 11:45 am
ASCO 2025
Gilead Sciences
glioblastoma
cell therapy
CAR-T
ASCO25: Novartis hopes Scemblix becomes new standard for CML-CP
Clinical Trials Arena
Mon, 06/2/25 - 11:39 am
ASCO 2025
Novartis
Scemblix
chronic myeloid leukemia
ASCO: AstraZeneca's oral SERD tied to 56% PFS benefit in phase 3 breast cancer trial
Fierce Biotech
Mon, 06/2/25 - 11:26 am
AstraZeneca
ASCO 2025
Camizestrant
clinical trials
breast cancer
ASCO: Amgen takes victory lap as Imdelltra prolongs life in small cell lung cancer
Fierce Pharma
Mon, 06/2/25 - 11:18 am
ASCO 2025
Amgen
Imdelltra
small cell lung cancer
ASCO25: J&J’s Carvykti shows strong efficacy across multiple myeloma risk groups
Clinical Trials Arena
Mon, 06/2/25 - 11:15 am
ASCO 2025
JNJ
Carvykti
cell therapy
Multiple Myeloma
ASCO25: Johnson & Johnson reports data from Phase I trial of prostate cancer drug
Clinical Trials Arena
Mon, 06/2/25 - 11:09 am
JNJ
clinical trials
ASCO 2025
pasritamig
bispecific antibodies
metastatic castration-resistant prostate cancer
ASCO: Bicara ties antibody to 46% 2-year survival rate for head and neck cancer subset
Fierce Biotech
Mon, 06/2/25 - 11:04 am
Bicara Therapeutics
ASCO 2025
ficerafusp alfa
Keytruda
squamous cell carcinoma of the head and neck

Pages